Topic cluster
GLP-1 Drug Comparisons & Pipeline: Wegovy, Zepbound, Foundayo & Beyond
Patients comparing branded GLP-1s — or evaluating the newer oral and pipeline drugs — need side-by-side trial data, not marketing copy. This cluster collects the head-to-head comparisons (tirzepatide vs semaglutide), the Foundayo / orforglipron deep-dives, and the pipeline drug articles (CagriSema, retatrutide, survodutide, MariTide, ecnoglutide).
15 research articles in this cluster · last updated 2026-05-23
Tirzepatide vs Semaglutide: A Head-to-Head Look at SURMOUNT and STEP
What the SURMOUNT and STEP trial families actually tell us about which GLP-1 drug produces more weight loss, fewer side effects, and longer-lasting results.
Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head
Foundayo (orforglipron) is the first oral GLP-1 for weight loss, FDA-approved April 1, 2026. How does it stack up against Wegovy and Zepbound? Side-by-side: 17.2 mg labeled-dose Foundayo 11.1% vs STEP-1 Wegovy 14.9% vs SURMOUNT-1 Zepbound 20.9%, $25 vs $499 vs $449, daily pill vs weekly injection.
What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation
Orforglipron (brand name Foundayo) is the first oral GLP-1 pill approved for weight loss, made by Eli Lilly and FDA-approved on April 1, 2026. This is the foundational explainer: what it is, who makes it, how the small-molecule GLP-1 mechanism works, what it's used for, how it compares to injectable GLP-1s, what it costs, and how to pronounce it.
Foundayo (orforglipron) Approved: The First Once-Daily Oral GLP-1 Pill for Weight Loss
Eli Lilly's Foundayo (orforglipron) was approved by the FDA on April 1, 2026, becoming the first once-daily small-molecule oral GLP-1 receptor agonist approved for chronic weight management. We walk through the ATTAIN-1 trial data, the dosing, the $25-$149/month pricing, and how the oral pill compares to injectable semaglutide and tirzepatide.
Orforglipron (Foundayo) Side Effects: ATTAIN-1 Trial Rates
What the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report for orforglipron side effects — the GI rates, the boxed MTC warning, the pancreatitis and gallbladder signal, and how the oral pill compares to injectable Wegovy and Zepbound.
Wegovy vs Ozempic vs Zepbound vs Mounjaro: Side-by-Side Comparison & Brand Cheat Sheet (2026)
Side-by-side comparison of every major GLP-1 — Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Foundayo — with verified efficacy data, dosing, indications, manufacturer, and cost. Plus the brand-name cheat sheet untangling which brand contains which active ingredient and which is identical to which.
Can You Take Phentermine With a GLP-1? The Combination Therapy Evidence and the Safety Concerns
Five hundred patients a month search 'can you take phentermine with semaglutide.' This is the evidence-based answer: there is no FDA approval for the combination, no randomized trial data on it, and real safety concerns about cardiovascular risk and stimulant exposure on top of GLP-1 therapy. Some obesity-medicine specialists do prescribe both, with monitoring. Here is the actual evidence and the risk framework.
Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs That Could Reach Approval in 2026-2027
Survodutide (Boehringer Ingelheim/Zealand), maridebart cafraglutide (MariTide, Amgen), and ecnoglutide (Sciwind/Pfizer) are the three most-watched GLP-1 pipeline drugs that aren't being made by Lilly or Novo. We walk through the verified phase 2 and phase 3 data on each, the mechanisms, and where they fit in the post-CagriSema, post-retatrutide landscape.
CagriSema REDEFINE: What Novo Nordisk's Amylin Combination Actually Showed
CagriSema (cagrilintide + semaglutide) is Novo Nordisk's next-generation amylin-GLP-1 combination injection. We walk through the REDEFINE 1 and REDEFINE 2 phase 3 trial results — 22.7% adherent weight loss in non-diabetic patients, 15.7% in patients with type 2 diabetes — and explain why the result missed the 25% target Novo had guided to but still beat semaglutide alone.
Retatrutide: What We Know About Lilly's Triple Agonist as TRIUMPH-4 Reads Out
Retatrutide is Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. The first phase 3 readout (TRIUMPH-4) reported 28.7% mean weight loss at the highest dose in adults with obesity and knee osteoarthritis. We walk through the published phase 2 data, the TRIUMPH-4 results, the open trials, and the new safety signal that emerged in the phase 3 program.
Berberine vs GLP-1s: What the Evidence Actually Shows About "Nature's Ozempic"
Berberine has been called "nature's Ozempic" on TikTok and in the supplement press. The peer-reviewed evidence is far narrower: a 2.07 kg average weight loss in a 12-RCT meta-analysis (Asbaghi 2020) versus 14.9% on semaglutide (STEP-1) and 20.9% on tirzepatide (SURMOUNT-1) — and an oral bioavailability under 1%. Here is the verified primary-source evidence.
What STEP-TEENS Showed: Semaglutide for Adolescents with Obesity
STEP-TEENS (Weghuber et al., NEJM 2022) is the trial that made Wegovy the first FDA-approved GLP-1 for adolescent obesity. 201 adolescents aged 12-17 randomized to weekly semaglutide or placebo for 68 weeks produced a 16.7-percentage-point separation in BMI change. Here's what the trial actually showed, what the AAP now recommends, and the long-term follow-up question that hasn't been answered yet.
Ozempic Without Diabetes: Off-Label Use for Weight Loss Evidence Review
Ozempic is FDA-approved only for type 2 diabetes — off-label for weight loss is legal under 21 USC 396 but rarely insurance-covered. Wegovy is the on-label equivalent (same semaglutide, 2.4 mg vs 2.0 mg max). SELECT trial extends CV safety to non-diabetic obese adults.
Wegovy for Teenagers: Patient + Parent Guide (Evidence Review)
Wegovy is FDA-approved for adolescents 12+ with obesity (BMI ≥ 95th percentile) based on STEP TEENS showing ~16% mean BMI reduction at 68 weeks. Saxenda is also approved 12+; Zepbound is not. AAP 2023 pairs pharmacotherapy with intensive lifestyle treatment.
Ozempic + Metformin: FDA Label, SUSTAIN-3/4 Evidence & Combination Therapy Review
Ozempic + metformin is a standard T2D combo. No clinically significant PK interaction (Ozempic FDA §7.1). SUSTAIN-3 and SUSTAIN-4 tested semaglutide added to metformin — additional A1c reduction and weight loss. GI effects additive; hypoglycemia rare without insulin/SU.